| Budget Amount *help |
¥177,710,000 (Direct Cost: ¥136,700,000、Indirect Cost: ¥41,010,000)
Fiscal Year 2014: ¥29,120,000 (Direct Cost: ¥22,400,000、Indirect Cost: ¥6,720,000)
Fiscal Year 2013: ¥30,550,000 (Direct Cost: ¥23,500,000、Indirect Cost: ¥7,050,000)
Fiscal Year 2012: ¥31,980,000 (Direct Cost: ¥24,600,000、Indirect Cost: ¥7,380,000)
Fiscal Year 2011: ¥31,720,000 (Direct Cost: ¥24,400,000、Indirect Cost: ¥7,320,000)
Fiscal Year 2010: ¥54,340,000 (Direct Cost: ¥41,800,000、Indirect Cost: ¥12,540,000)
|
|---|
| Outline of Final Research Achievements |
Cancer is caused by genetic abnormalities, which cause alterations in characteristics of cells, leading to deregulated proliferation of abnormal cells, where the difference in genetic alterations defines heterogeneity of cancer in different individuals. In this study, we have comprehensively investigated genetic alterations in a variety of cancers, including myelodysplastic syndromes (MDS), Down syndrome-related myeloproliferative neoplasm, clear cell renal carcinoma (ccRCC), lower-grade gliomas. Through these studies, we delineated the entire pictures of these cancers, newly identifying mutational targets that characterize each tumor types, including RNA splicing factors, the cohesin complex in MDS, mTOR and TCEB1 in ccRCC and many other genes plausible for drug targets. Our findings will contribute to the development of novel diagnostics and therapeutics.
|
